EUVIMEDEUVIMED entdecken
Fallbericht

Colonic mucosal diffuse congestion associated with Osimertinib

Xiao-Jun Ren iD, Ming-Hong Lei, Ying-Xia Cheng, Yun Luo

Journal of Oncology Pharmacy Practice · 2023

DOI: 10.1177/10781552231184182 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Oncology Pharmacy Practice, 2023. Verfasst von Xiao-Jun Ren und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology & Hepatology, Dazhou Integrated TCM and Western Medicine Hospital: Dazhou Second People's Hospital, Dazhou, Sichuan, C…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Non-small cell lung cancer (NSCLC) is the most common histological subtype of lung cancer. Osimertinib has been recommended as first-line treatment of advanced NSCLC with EGFR mutations. Previous studies have only reported cases of gastrointestinal bleeding due to Erlotinib and gefitinib, but to date, always no cases of gastrointestinal bleeding due to Osimertinib have been reported. Case Report We report a case of a female patient with NSCLC with EFGR mutation. After 1.5 years of treatment with Osimertinib, a colonoscopy showed diffuse congestion of the colonic mucosa. Management and Outcome The patient’s symptoms of blood in the stool disappeared, after stopping Osimertinib and giving mucosal protection treatment for 1 week.

Discussion

Osimertinib may have contributed to gastrointestinal bleeding because no recurrent bleeding was observed after discontinuation of treatment. Physicians and patients should be aware that osimertinib may increase the risk of gastrointestinal bleeding.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansFemaleProtein Kinase InhibitorsErbB ReceptorsAniline CompoundsMutationGastrointestinal HemorrhageAcrylamidesIndolesPyrimidines

Stichwörter der Autor:innen

EGFR mutationLung cancerOsimertinibcase report

Substanzen

Protein Kinase InhibitorsErbB ReceptorsAniline CompoundsosimertinibAcrylamidesIndolesPyrimidines

Autor:innen und Institutionen

  • Department of Gastroenterology & Hepatology, Dazhou Integrated TCM and Western Medicine Hospital: Dazhou Second People's Hospital, Dazhou, Sichuan, China.
  • Department of Gastroenterology & Hepatology, Bishan District Traditional Chinese Medicine Hospital, Bishan, Chongqing, China.
  • Ningxia Medical University, Yinchuan, Ningxia, China.

ORCID-Profile: Xiao-Jun Ren

Zitieren

APA

Ren, X. J., Lei, M. H., Cheng, Y. X., & Luo, Y. (2023). Colonic mucosal diffuse congestion associated with Osimertinib. Journal of Oncology Pharmacy Practice. https://doi.org/10.1177/10781552231184182

Vancouver

Ren XJ, Lei MH, Cheng YX, Luo Y. Colonic mucosal diffuse congestion associated with Osimertinib. Journal of Oncology Pharmacy Practice. 2023. doi:10.1177/10781552231184182

BibTeX
@article{Ren2023,
  author = {Ren, Xiao-Jun and Lei, Ming-Hong and Cheng, Ying-Xia and Luo, Yun},
  title = {Colonic mucosal diffuse congestion associated with Osimertinib},
  journal = {Journal of Oncology Pharmacy Practice},
  year = {2023},
  doi = {10.1177/10781552231184182}
}
Kostenlos starten →